Study of tiprelestat for pulmonary arterial hypertension
Part of Lungs & breathing clinical trials.
This study tests a new drug, tiprelestat, added to your current treatment for pulmonary arterial hypertension (PAH). It aims to see if it improves your symptoms and exercise ability.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with PAH (Group 1 pulmonary hypertension).
- You are in functional class II, III, or IV despite your current treatment.
- You have been on stable doses of your PAH medications for at least 90 days (or 6 months for Sotatercept).
- You can walk between 100 and 500 meters in 6 minutes.
- You are not pregnant or breastfeeding, and if you could become pregnant, you agree to use two reliable forms of birth control.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how a medication called sotatercept affects the blood vessels in the lungs over time. It aims to see if it can help improve how the heart and lungs work in people with pulmonary hypertension.
This study tests a drug called treprostinil to see if it is safe and effective for people with intermediate-risk pulmonary arterial hypertension (PAH), a condition of high blood pressure in the lungs. If you join, you may receive the study drug along with your usual PAH medications, which could help improve your symptoms and slow the disease.
This trial tests a new medication called REGN13335 for people with pulmonary arterial hypertension (PAH). It aims to see if the drug can improve symptoms and function compared to standard care alone.
This trial tests a new combination of three medicines (including an experimental drug called sotatercept) for people recently diagnosed with PAH. The goal is to see if this early, powerful treatment works better than standard care in improving heart and lung function.
This trial tests whether adding the study drug sotatercept to your current PAH therapy along with a home exercise program can help you feel better and be more active. It's for people with certain types of PAH who are stable on their current treatment.
This study tests whether switching from the oral medicine selexipag to an inhaled medicine called treprostinil can improve symptoms or side effects in people with pulmonary arterial hypertension (PAH). It may be an option if you are not getting enough benefit or are having trouble tolerating selexipag.
Hear when a new Pulmonary Arterial Hypertension (PAH) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.